Despite reduced incidence and morbidity in the post-cART HIV population, CMVR continues to cause vision loss amongst HIV and non-HIV patients. Diagnosis remains primarily clinical, and therapy centers upon immune reconstitution along with systemic and/or intravitreal antivirals. Further studies are necessary to determine whether advanced imaging can influence management, and whether novel antiviral agents or adoptive immune transfer have a role in treatment of drug-resistance CMVR.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- human immunodeficiency virus
- hepatitis c virus
- hiv aids
- men who have sex with men
- end stage renal disease
- newly diagnosed
- ejection fraction
- high resolution
- cell therapy
- south africa
- prognostic factors
- peritoneal dialysis
- risk factors
- epstein barr virus
- patient reported outcomes
- diabetic retinopathy
- mesenchymal stem cells
- endothelial cells
- photodynamic therapy
- case control
- replacement therapy
- drug induced
- fluorescence imaging